BD (Becton, Dickinson and Company) has deepened its collaboration with injection-system specialist Ypsomed by developing a 5.5 mL version of its Neopak XtraFlow glass prefillable syringe. The new syringe features an 8 mm needle and thinner-wall cannulas to support higher-volume, high-viscosity biologics and is fully compatible with Ypsomed’s YpsoMate 5.5 autoinjector platform. Samples for feasibility studies are slated for mid-2026 and will allow pharmaceutical partners to accelerate development of combination products while reducing time-to-market for large-dose subcutaneous therapies in oncology, autoimmune and rare diseases.

BD has secured FDA 510(k) clearance for its EnCor EnCompass breast biopsy system, paving the way for a U.S. launch in early 2026. The system offers clinicians adjustable vacuum levels, real-time tissue sampling feedback and a modular handpiece designed to improve procedural flexibility. Clinical validation studies showed a 25 percent reduction in procedure time versus the prior-generation EnCor system, while maintaining diagnostic accuracy above 95 percent. BD expects EnCor EnCompass to bolster its diagnostic imaging portfolio and drive mid-single-digit revenue growth in its interventional oncology segment next year.